Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis


Tahan V., Eren F. , Avsar E., Yavuz D. , Yuksel M. , Emekli E., et al.

DIGESTIVE DISEASES AND SCIENCES, cilt.52, ss.3465-3472, 2007 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 52 Konu: 12
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1007/s10620-007-9756-x
  • Dergi Adı: DIGESTIVE DISEASES AND SCIENCES
  • Sayfa Sayısı: ss.3465-3472

Özet

Rosiglitazone is an insulin-sensitizing agent. We aimed to assess the effects of rosiglitazone on a methionine- and choline-deficient diet (MCDD) model of nonalcoholic steatohepatitis (NASH) in rats. Wistar rats were fed either MCDD or a control diet in the 4-week induction study; they were given saline or 4 mg/kg/day rosiglitazone. After the induction study period, the rats were divided into four groups and fed MCDD or given a control diet for an additional 8 weeks and received saline or rosiglitazone. Serum and tissue samples were obtained. Rosiglitazone improved inflammation in NASH and improved ALT, alkaline phosphatase, and interleukin-6 levels in the induction study and interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha levels in the treatment study. Our preliminary study is the first to show the anti-inflammatory effects of rosiglitazone in NASH. Rosiglitazone's effect on cytokines may be a key mechanism of its anti-inflammatory effect in NASH.